ZA200808963B - Compounds for the treatment of metabolic disorders - Google Patents
Compounds for the treatment of metabolic disordersInfo
- Publication number
- ZA200808963B ZA200808963B ZA200808963A ZA200808963A ZA200808963B ZA 200808963 B ZA200808963 B ZA 200808963B ZA 200808963 A ZA200808963 A ZA 200808963A ZA 200808963 A ZA200808963 A ZA 200808963A ZA 200808963 B ZA200808963 B ZA 200808963B
- Authority
- ZA
- South Africa
- Prior art keywords
- compounds
- treatment
- metabolic disorders
- metabolic
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74763806P | 2006-05-18 | 2006-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200808963B true ZA200808963B (en) | 2009-11-25 |
Family
ID=38723959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200808963A ZA200808963B (en) | 2006-05-18 | 2008-10-20 | Compounds for the treatment of metabolic disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7935689B2 (enExample) |
| EP (1) | EP2019673A4 (enExample) |
| JP (1) | JP2009537559A (enExample) |
| KR (1) | KR20090010035A (enExample) |
| CN (1) | CN101437506A (enExample) |
| AU (1) | AU2007253929B2 (enExample) |
| CA (1) | CA2651598A1 (enExample) |
| IL (1) | IL195203A0 (enExample) |
| MX (1) | MX2008014560A (enExample) |
| NZ (1) | NZ572681A (enExample) |
| WO (1) | WO2007137008A2 (enExample) |
| ZA (1) | ZA200808963B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101106631B1 (ko) * | 2003-02-13 | 2012-01-20 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| US20090176885A1 (en) * | 2006-02-02 | 2009-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2240024A4 (en) * | 2008-01-15 | 2014-05-21 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| NZ631569A (en) * | 2012-02-28 | 2016-10-28 | Piramal Entpr Ltd | Phenyl alkanoic acid derivatives as gpr agonists |
| WO2015028960A1 (en) * | 2013-08-28 | 2015-03-05 | Piramal Enterprises Limited | Substituted heterocyclic derivatives as gpr agonists and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE136018T1 (de) | 1991-05-09 | 1996-04-15 | Hoffmann La Roche | Substituierte carbonsäurederivate |
| DE4122315A1 (de) * | 1991-07-05 | 1993-01-07 | Basf Ag | 2-aryl-2,2-dialkoxyessigsaeurealkylester, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von arylglyoxylsaeureester |
| FR2781222A1 (fr) * | 1998-07-17 | 2000-01-21 | Lipha | Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation |
| JP2002371033A (ja) * | 2001-04-10 | 2002-12-26 | Sankyo Co Ltd | ω−アリール−α−置換脂肪酸誘導体 |
| CN100344616C (zh) | 2001-06-12 | 2007-10-24 | 维尔斯达医疗公司 | 用于治疗代谢失调的化合物 |
| AU2003286728A1 (en) | 2002-11-01 | 2004-06-07 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| KR101106631B1 (ko) * | 2003-02-13 | 2012-01-20 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| US7863313B2 (en) * | 2003-04-07 | 2011-01-04 | Cortical Pty Ltd | Methods for the treatment of inflammatory diseases |
| PL1633340T3 (pl) | 2003-04-15 | 2011-04-29 | Wellstat Therapeutics Corp | Związki do leczenia chorób metabolicznych |
| CA2521589C (en) | 2003-04-22 | 2011-11-01 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| KR101192272B1 (ko) * | 2003-04-30 | 2012-10-17 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| WO2005018628A1 (en) | 2003-08-20 | 2005-03-03 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CA2602854C (en) | 2005-04-01 | 2013-05-14 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009531280A (ja) | 2006-01-25 | 2009-09-03 | ウェルスタット セラピューティクス コーポレイション | 代謝障害を処置するための化合物 |
| EP1976378A4 (en) | 2006-01-25 | 2010-06-09 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
-
2007
- 2007-05-11 NZ NZ572681A patent/NZ572681A/en not_active IP Right Cessation
- 2007-05-11 KR KR1020087026318A patent/KR20090010035A/ko not_active Withdrawn
- 2007-05-11 CA CA002651598A patent/CA2651598A1/en not_active Abandoned
- 2007-05-11 MX MX2008014560A patent/MX2008014560A/es active IP Right Grant
- 2007-05-11 JP JP2009511181A patent/JP2009537559A/ja active Pending
- 2007-05-11 CN CNA2007800165233A patent/CN101437506A/zh active Pending
- 2007-05-11 US US12/300,239 patent/US7935689B2/en active Active - Reinstated
- 2007-05-11 EP EP07783635A patent/EP2019673A4/en not_active Withdrawn
- 2007-05-11 AU AU2007253929A patent/AU2007253929B2/en not_active Ceased
- 2007-05-11 WO PCT/US2007/068745 patent/WO2007137008A2/en not_active Ceased
-
2008
- 2008-10-20 ZA ZA200808963A patent/ZA200808963B/xx unknown
- 2008-11-10 IL IL195203A patent/IL195203A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007253929A1 (en) | 2007-11-29 |
| AU2007253929B2 (en) | 2011-07-21 |
| JP2009537559A (ja) | 2009-10-29 |
| EP2019673A4 (en) | 2010-06-16 |
| KR20090010035A (ko) | 2009-01-28 |
| EP2019673A2 (en) | 2009-02-04 |
| NZ572681A (en) | 2012-01-12 |
| WO2007137008A3 (en) | 2008-08-28 |
| US7935689B2 (en) | 2011-05-03 |
| CN101437506A (zh) | 2009-05-20 |
| US20090163576A1 (en) | 2009-06-25 |
| WO2007137008A2 (en) | 2007-11-29 |
| CA2651598A1 (en) | 2007-11-29 |
| IL195203A0 (en) | 2009-08-03 |
| MX2008014560A (es) | 2008-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1976377A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| EP1983972A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| IL195203A0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA200803440B (en) | Compounds for the treatment of metabolic disorders | |
| ZA200900734B (en) | Combination treatment for metabolic disorders | |
| IL192692A0 (en) | Compounds for the treatment of inflammatory disorders | |
| ZA201007127B (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| ZA200805645B (en) | Compounds for the treatment of metabolic disorders | |
| IL194076A0 (en) | Imidazolothiazole compounds for the treatment of disease | |
| IL192691A0 (en) | Hydantoin compounds for the treatment of inflammatory disorders | |
| IL194189A0 (en) | Combination treatment of metabolic disorders | |
| PL1982178T3 (pl) | Sposoby leczenia zaburzeń afektywnych | |
| IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
| EP2240024A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| IL192982A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL198432A0 (en) | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | |
| GB0604782D0 (en) | Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders | |
| HK1121935A (en) | Compounds for the treatment of metabolic disorders | |
| HK1122187A (en) | Compounds for the treatment of metabolic disorders | |
| HK1121917A (en) | Compounds for the treatment of metabolic disorders | |
| HK1120724A (en) | Compounds for the treatment of metabolic disorders | |
| HK1124486A (en) | Compounds for the treatment of metabolic disorders | |
| HK1124246A (en) | Compounds for the treatment of metabolic disorders | |
| HK1144778A (en) | Compounds for the treatment of metabolic disorders |